An 8-Week Refractory Chronic Cough Study (MK-7264-021)
Public ClinicalTrials.gov record NCT02612623. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Parallel, Double-Blind Study to Assess the Efficacy and Tolerability of AF-219 in Subjects With Refractory Chronic Cough
Study identification
- NCT ID
- NCT02612623
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Enrollment
- 24 participants
Conditions and interventions
Conditions
Interventions
- Gefapixant Drug
- Placebo (for gefapixant) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 16, 2015
- Primary completion
- May 3, 2016
- Completion
- May 17, 2016
- Last update posted
- Nov 24, 2019
2015 – 2016
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Afferent Investigative Site | Mission Viejo | California | — | — |
| Afferent Investigative Site | San Jose | California | — | — |
| Afferent Investigative Site | Colorado Springs | Colorado | — | — |
| Afferent Investigative Site | Largo | Florida | — | — |
| Afferent Investigative Site | Charlotte | North Carolina | — | — |
| Afferent Investigative Site | Tulsa | Oklahoma | — | — |
| Afferent Investigative Site | Dallas | Texas | — | — |
| Afferent Investigative Site | San Antonio | Texas | — | — |
| Afferent Investigative Site | Bellevue | Washington | — | — |
| Afferent Investigative Site | Greenfield | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02612623, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 24, 2019 · Synced Jun 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02612623 live on ClinicalTrials.gov.